Serum levels of S-100B protein and neuron-specific enolase in glioma patients: A pilot study

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2511-2514

  Vos, Maaike J ^a   Postma, Tjeerd J ^a   Martens, Frans ^a   Uitdehaag, Bernard M J ^a   Blankenstein, Marines A ^a   Vandertop, W Peter ^a   Slotman, Ben J ^a   Heimans, Jan J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glioma; Neuron specific enolase; S 100B protein

Indexed keywords

LOMUSTINE; NEURON SPECIFIC ENOLASE; PROCARBAZINE; PROTEIN S100B; VINCRISTINE;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MALE; PATIENT CODING; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SKULL SURGERY; SURVIVAL RATE;

ADULT; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PHOSPHOPYRUVATE HYDRATASE; PILOT PROJECTS; PROGNOSIS; S100 PROTEINS;

EID: 4444289405     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT et al: Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma 17: 113-122, 2000.
2. Wiesmann M, Missler U, Hagenström H and Gottmann D: S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 139: 1155-1160, 1997.
3. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S and Herrmann M: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 30: 1190-1195, 1999.
4. Hermann M, Ebert AD, Galazky I, Wunderlich MT, Kunz WS and Huth C: Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke 31: 645-650, 2000.
5. Bonfrer JMG, Korse CM, Nieweg OE and Rankin EM: The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77: 2210-2214, 1998.
6. Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D et al: Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 2: 361-363, 1983.
7. Abrams J, Doyle LA and Aisner J: Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 15: 261-277, 1988.
8. Fagnart OC, Sindic CJM and Laterre C: Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34: 1387-1391, 1988.
9. Van den Doel EMH, Rijksen G, Roholl PJM, van Veelen CWM and Staal GEJ: Enolase isoenzymes in human gliomas. J Neurosurg 65: 345-353, 1986.
10. Taomoto K, Kokunai T, Okuda T, Tamaki N, Matsumoto S and Hashimoto N: The value of neuron specific enolase (NSE) in patients with brain tumors. No To Shinkei 39: 169-173, 1987.
11. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V et al: Serum S100β. A noninvasive marker of blood-brain barrier function and brain lesions. Cancer 97: 2806-2813, 2003.
12. Wiesmann M, Missler U, Gottmann D and Gehring S: Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 44: 1056-1058, 1998.